Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis

Fujita, Ryo; Endo, Tsutomu; Takahata, Masahiko; Haraya, Kentaro; Suzuki, Hisataka; Oda, Ichiro; Kanayama, Masahiro; Asano, Tsuyoshi; Shigenobu, Keiichi; Iwata, Atsushi; Yamada, Kei; Takeuchi, Hirohito; Ohura, Hisanori; Yoneoka, Daisuke; Iwasaki, Norimasa

doi:10.1007/s00774-022-01347-1

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the eventual discontinuation of teriparatide treatment poses a problem. In reports from Japan, the 12-month continuation rates of daily, once-weekly, and twice-weekly teriparatide treatments were only 43.1%, 23.5%, and 47.5%, respectively [ 32 , 33 ]. As in our present patient, nausea was cited as one of the major reasons for the difficulty with teriparatide continuation [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

“…In reports from Japan, the 12-month continuation rates of daily, once-weekly, and twice-weekly teriparatide treatments were only 43.1%, 23.5%, and 47.5%, respectively [ 32 , 33 ]. As in our present patient, nausea was cited as one of the major reasons for the difficulty with teriparatide continuation [ 32 , 33 ]. If teriparatide is unavailable because of side effects such as nausea and dizziness, an alternative treatment for PLO is necessary.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

et al. 2022

View full text Add to dashboard Cite

Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis that occurs mainly in the third trimester or immediately after delivery; one of its most common symptoms is back pain caused by a vertebral fracture. The pathogenesis of PLO is unclear, and there is no accepted consensus regarding the treatment of PLO. Although treatments with drugs such as bisphosphonate, strontium ranelate, denosumab, and teriparatide were reported, there is no report of a patient with PLO treated with romosozumab. We present the first case of a patient with PLO treated with romosozumab following 4-month teriparatide treatment. A 34-year-old primiparous and breastfeeding Japanese woman experienced severe low back pain 1 month postdelivery. She was diagnosed with PLO on the basis of low bone marrow density (BMD) and multiple vertebral fractures with no identified cause of secondary osteoporosis. She was treated with teriparatide injection for 4 months, but the treatment was discontinued because of the patient feeling severe nausea after every teriparatide injection and the appearance of new vertebral fractures. Thereafter, we used romosozumab for 12 months. After the romosozumab treatment, her BMD was increased from the baseline by 23.6% at L1–L4, 6.2% at the femoral neck, and 11.2% at the total hip. Treating PLO with 12-month romosozumab after 4 months of teriparatide injection remarkably increased the BMD of the lumbar spine, femoral neck, and total hip without subsequent fracture. Romosozumab has potential as a therapeutic option to improve the BMD and reduce the subsequent fracture risk of patients with PLO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

et al. 2022

View full text Add to dashboard Cite

show abstract

Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis

et al. 2023

View full text Add to dashboard Cite

A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)

Soen,

Uemura,

Tanaka

et al. 2024

J Bone Miner Metab

View full text Add to dashboard Cite

Introduction This study aimed to compare treatment satisfaction with two dosing regimens (two teriparatide [TPTD] self-injection systems) in osteoporosis patients at high risk of fracture. Materials and methods In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years. The primary endpoint was overall satisfaction and secondary endpoints were satisfaction with treatment effectiveness and with utility of the self-injection device. Changes in quality of life (QOL) assessed by EuroQol-5 Dimension, pain assessed by visual analogue scale (VAS), and anthropometric parameters were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs). Results The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively. After 26 weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1/D-TPTD and 2/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (p > 0.05) were observed. However, several items of satisfaction with the utility of the injection device were significantly higher in the 2/W-TPTD group (p < 0.05). Statistical improvements from baseline values were observed in QOL and pain VAS in both groups (p < 0.05). No serious AEs were reported. Conclusion The between-group similarity of overall treatment satisfaction and effectiveness scores and between-group difference in satisfaction with the utility of the self-injection device was useful information for real-world treatment of osteoporosis. Both medication regimens were well tolerated.

show abstract

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis

Cited by 7 publications

References 31 publications

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis

A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)

Contact Info

Product

Resources

About